Description

TB-500 — Research Peptide

Product Description

TB-500 is a synthetic peptide derived from the actin-binding region of Thymosin Beta-4 (Tβ4). It represents a short active fragment of the larger 43-amino-acid thymosin β4 protein, believed to retain several of the parent molecule’s regenerative signaling properties.

The peptide is widely studied in experimental models related to:

• connective tissue repair

• angiogenesis (formation of new blood vessels)

• cell migration

• anti-fibrotic signaling

• wound healing processes

Unlike the full Thymosin Beta-4 protein, TB-500 represents a smaller functional domain believed to interact with actin cytoskeleton regulation, which plays an important role in cell movement and tissue remodeling.

Most available data for TB-500 comes from preclinical studies or extrapolation from Thymosin Beta-4 research, which contains a much larger body of literature.

Verified references

• TB-500 identification / active-site background: https://pubmed.ncbi.nlm.nih.gov/23084823/

• Active-site review of Tβ4 fragments including LKKTETQ: https://pubmed.ncbi.nlm.nih.gov/20179146/

• Review of thymosin β4 functions in repair/regeneration: https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/

---

Key Research Characteristics

Compound: TB-500
Parent molecule: Thymosin Beta-4
Functional region: Actin-binding domain
Peptide fragment: amino acids 17–23 of thymosin beta-4
Alternative name: N-acetyl-LKKTETQ

Primary research areas include:

• wound healing models

• tissue regeneration

• angiogenesis signaling

• anti-fibrotic activity

• connective tissue repair

Verified references

• TB-500 / Ac-LKKTETQ background: https://pubmed.ncbi.nlm.nih.gov/38382158/

• Active-site fragment review: https://pubmed.ncbi.nlm.nih.gov/20179146/

• Actin-binding site mapping in Tβ4: https://pubmed.ncbi.nlm.nih.gov/8617195/

---

Evidence Base

The scientific literature surrounding TB-500 itself is limited, with only a small number of direct studies available.

However, Thymosin Beta-4, the parent molecule, has over 1,000 scientific publications, many of which describe regenerative and cytoprotective effects that are hypothesized to relate to the active fragment used in TB-500.

Because TB-500 is a synthetic fragment, its pharmacology is often interpreted through mechanistic overlap with thymosin β4 signaling pathways.

Verified references

• TB-500 detection / background paper explicitly noting limited direct biological documentation: https://pubmed.ncbi.nlm.nih.gov/38382158/

• Tβ4 active-site review: https://pubmed.ncbi.nlm.nih.gov/20179146/

• General Tβ4 review: https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/

---

Experimental Exposure Ranges (Educational Context Only)

⚠️ These values represent experimental discussions and research contexts.
They are not medical guidance.

Soft tissue research contexts

• 500 mcg – 1 mg once or twice daily

• Total daily exposure 500 mcg – 2 mg

These exposure levels are commonly discussed in experimental connective-tissue healing models.

Alternative high-dose experimental ranges

Some protocols discussed in research communities involve:

• 5–10 mg every 5–7 days

These ranges are derived primarily from animal models and extrapolated experimental protocols.

Verified references for research context / limitations

• Direct TB-500 metabolism / rat urine paper: https://pubmed.ncbi.nlm.nih.gov/38382158/

• Equine detection paper for TB-500: https://pubmed.ncbi.nlm.nih.gov/23084823/

• WADA-funded TB-500 metabolism project summary: https://www.wada-ama.org/en/resources/scientific-research/investigation-vitroex-vivo-tb-500-metabolism-synthesis-relevant

---

Expanded Research Overview

(Scientific background and mechanisms)

---

Molecular Origin

TB-500 originates from the actin binding region of Thymosin Beta-4, a naturally occurring protein found in many mammalian tissues.

Thymosin Beta-4 consists of 43 amino acids and plays roles in:

• cytoskeletal organization

• cell migration

• angiogenesis

• wound healing

The synthetic fragment TB-500 represents the core active sequence thought to mediate many of these functions.

Verified references

• Tβ4 active-site review: https://pubmed.ncbi.nlm.nih.gov/20179146/

• TB-500 / LKKTETQ doping analysis background: https://pubmed.ncbi.nlm.nih.gov/23084823/

• Tβ4 actin binding site mapping: https://pubmed.ncbi.nlm.nih.gov/8617195/

---

Mechanistic Profile

---

Actin Binding and Cytoskeleton Regulation

The primary biological activity of TB-500 relates to actin binding.

Actin is a key structural protein forming the cytoskeleton of cells, which controls:

• cell shape

• cell movement

• intracellular transport

• tissue repair processes

By interacting with actin pathways, TB-500 is believed to promote:

• cell migration

• structural remodeling

• tissue regeneration signaling

Verified references

• Actin-binding site mapping in Tβ4: https://pubmed.ncbi.nlm.nih.gov/8617195/

• TB-500 / active region identification: https://pubmed.ncbi.nlm.nih.gov/23084823/

• Active-site review: https://pubmed.ncbi.nlm.nih.gov/20179146/

---

Cell Migration Signaling

In vitro studies demonstrate that TB-500 can stimulate migration of several cell types, including:

• keratinocytes

• endothelial cells

• fibroblasts

Cell migration is a fundamental process in wound healing, allowing repair cells to reach damaged tissue.

Verified references

• Tβ4 wound-healing paper showing keratinocyte migration, collagen deposition, angiogenesis: https://pubmed.ncbi.nlm.nih.gov/10469335/

• Diabetic / aged wound-healing paper showing LKKTETQ fragment promoted repair comparable to parent molecule: https://pubmed.ncbi.nlm.nih.gov/12581423/

• Active-site review: https://pubmed.ncbi.nlm.nih.gov/20179146/

---

Angiogenesis

Experimental data suggests TB-500 may promote angiogenesis, the formation of new blood vessels.

Angiogenesis is essential for tissue recovery because it allows:

• delivery of oxygen

• delivery of nutrients

• removal of metabolic waste

This process is critical in:

• connective tissue repair

• ischemic injury models

• wound healing environments

Verified references

• Tβ4 wound-healing / angiogenesis paper: https://pubmed.ncbi.nlm.nih.gov/10469335/

• Active-site review noting LKKTETQ promotes angiogenesis: https://pubmed.ncbi.nlm.nih.gov/20179146/

• Tβ4 vascular review: https://ora.ox.ac.uk/objects/uuid:ab536790-9774-4f42-b794-13cf7398aba6/files/m54dfc6902dab13d6cd6f551b42f8f134

---

Anti-Fibrotic Activity

Animal and cell models suggest TB-500 may demonstrate anti-fibrotic effects, meaning it may help regulate scar tissue formation.

Fibrosis occurs when excessive collagen is deposited during healing, producing stiff, dysfunctional tissue.

TB-500 appears to influence pathways that regulate:

• collagen deposition

• fibroblast activity

• extracellular matrix remodeling

This mechanism is thought to support more organized tissue repair.

Verified references

• Tβ4 review covering reduced scar formation / fibrosis: https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/

• Tβ4 post-MI paper showing reduced interstitial collagen fraction and improved cardiac remodeling: https://pmc.ncbi.nlm.nih.gov/articles/PMC4187393/

• Recent cardiac remodeling / antifibrotic paper: https://www.mdpi.com/1422-0067/26/9/4131

---

Preclinical Research Observations

Studies using TB-500 in laboratory models have reported effects such as:

• accelerated wound closure

• increased keratinocyte migration

• improved collagen organization

• enhanced angiogenesis

• reduction in fibrotic scar tissue

One experimental setup applied 0.01–0.05% topical TB-500 / LKKTETQ-related wound formulation logic to wound sites for 10 days, producing faster healing relative to control groups.

These outcomes were comparable to those observed with thymosin beta-4.

Verified references

• Direct diabetic / aged wound-healing paper with LKKTETQ fragment comparable to parent molecule: https://pubmed.ncbi.nlm.nih.gov/12581423/

• Foundational Tβ4 wound-healing paper: https://pubmed.ncbi.nlm.nih.gov/10469335/

• Dermal healing review: https://pubmed.ncbi.nlm.nih.gov/27450738/

---

Pharmacokinetics

Precise pharmacokinetic data in humans is limited.

Estimated properties include:

Estimated half-life:
approximately 24–36 hours (hypothesized)

The parent protein Thymosin Beta-4 has a serum half-life of approximately 1.8–2.1 hours, but structural modification of TB-500 may extend functional activity.

Direct human pharmacokinetic data remains limited.

Verified references

• TB-500 metabolism / metabolites in vitro and rats: https://pubmed.ncbi.nlm.nih.gov/38382158/

• Equine plasma / urine detection paper: https://pubmed.ncbi.nlm.nih.gov/23084823/

• WADA metabolism project summary: https://www.wada-ama.org/en/resources/scientific-research/investigation-vitroex-vivo-tb-500-metabolism-synthesis-relevant

---

Detection and Metabolism

Animal models suggest TB-500 metabolites may be detectable for relatively short periods.

Examples include:

Horse model

• metabolites detected 9–11 hours

Rodent models

• metabolites detected up to ~48–72 hours

These findings suggest rapid metabolism by peptidase enzymes.

Verified references

• Equine detection study: https://pubmed.ncbi.nlm.nih.gov/23084823/

• TB-500 metabolite study in rats: https://pubmed.ncbi.nlm.nih.gov/38382158/

• WADA project summary: https://www.wada-ama.org/en/resources/scientific-research/investigation-vitroex-vivo-tb-500-metabolism-synthesis-relevant

---

Research Applications

TB-500 is most frequently investigated in experimental models involving:

Connective Tissue Injury

• tendon damage

• ligament injury

• muscle tears

• wound healing

These tissues typically heal slowly due to limited vascular supply.

Verified references

• Direct LKKTETQ / wound repair in aged and diabetic mice: https://pubmed.ncbi.nlm.nih.gov/12581423/

• Tβ4 wound-healing / keratinocyte migration / collagen deposition paper: https://pubmed.ncbi.nlm.nih.gov/10469335/

• Dermal healing review: https://pubmed.ncbi.nlm.nih.gov/27450738/

---

Cardiovascular Research

Experimental research involving Thymosin Beta-4 signaling pathways has suggested potential effects on:

• endothelial cell migration

• vascular repair

• ischemic injury recovery

However, these mechanisms are largely derived from Tβ4 studies rather than TB-500 itself.

Verified references

• Tβ4 prevents cardiac rupture / improves function post-MI: https://pmc.ncbi.nlm.nih.gov/articles/PMC4187393/

• Tβ4 treatment after myocardial infarction: https://pmc.ncbi.nlm.nih.gov/articles/PMC3664360/

• Tβ4 promotes survival and angiogenesis of EPCs in infarcted myocardium: https://pubmed.ncbi.nlm.nih.gov/28440414/

---

Nervous System Models

Some experimental work indicates thymosin beta-4 signaling may support neurite growth and nerve repair.

TB-500 may theoretically influence similar pathways due to shared active domains.

Verified references

• General Tβ4 review with CNS / regeneration coverage: https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/

• Tβ4-derived peptides and neuroinflammation (newer preclinical work): https://www.sciencedirect.com/science/article/abs/pii/S1567576925020867

---

Human / Clinical Trial Context

Direct TB-500 human clinical trials have not been established.

However, Thymosin Beta-4 / RGN-259 has entered clinical development in ophthalmology.

Verified trials / studies

• Dry eye Phase III trial listing: https://clinicaltrials.gov/study/NCT02974907

• Earlier dry eye trial listing: https://clinicaltrials.gov/study/NCT01387347

• Phase II dry-eye publication: https://pubmed.ncbi.nlm.nih.gov/26056426/

• Severe dry eye publication: https://pubmed.ncbi.nlm.nih.gov/25826322/

• Neurotrophic keratopathy Phase III publication: https://pubmed.ncbi.nlm.nih.gov/36613994/

---

Limitations of Current Evidence

A critical scientific consideration is that direct TB-500 research remains limited.

Key points include:

• Only a small number of direct TB-500 studies exist

• Most mechanistic understanding derives from Thymosin Beta-4 research

• Human clinical trials for TB-500 have not been conducted

Therefore, conclusions regarding efficacy should be interpreted cautiously.

Verified references

• Direct TB-500 paper explicitly stating the biological effects of TB-500 itself are not documented to the same extent: https://pubmed.ncbi.nlm.nih.gov/38382158/

• Active-site / fragment review: https://pubmed.ncbi.nlm.nih.gov/20179146/

• Tβ4 review: https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/

---

Regulatory Status

TB-500 is not currently approved as a pharmaceutical medication.

The compound is commonly categorized as a research peptide.

Because of limited clinical data, many regulatory frameworks restrict its medical use.

Verified references

• Equine anti-doping analytical paper: https://pubmed.ncbi.nlm.nih.gov/23084823/

• WADA metabolism project summary: https://www.wada-ama.org/en/resources/scientific-research/investigation-vitroex-vivo-tb-500-metabolism-synthesis-relevant

---

Safety Considerations

Because controlled human trials are limited, long-term safety data remains incomplete.

Important considerations include:

• unknown long-term effects

• limited pharmacokinetic data in humans

• absence of large-scale clinical trials

Verified references

• Direct TB-500 metabolism / wound-healing assay paper: https://pubmed.ncbi.nlm.nih.gov/38382158/

• Tβ4 review: https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/

• Tβ4 ophthalmic clinical safety context: https://pubmed.ncbi.nlm.nih.gov/26056426/

---

Summary Perspective

TB-500 represents a synthetic active fragment of thymosin beta-4 with promising biological properties in experimental models.

Research suggests potential involvement in:

• connective tissue repair

• angiogenesis

• cell migration

• anti-fibrotic tissue remodeling

However, most of the scientific foundation originates from the broader thymosin beta-4 research field rather than TB-500 itself.

Further clinical studies are required to determine the peptide’s full therapeutic potential.

Verified references

• TB-500 metabolism / limitations paper: https://pubmed.ncbi.nlm.nih.gov/38382158/

• Tβ4 review: https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/

• Active-site fragment review: https://pubmed.ncbi.nlm.nih.gov/20179146/